Difference between revisions of "Team:Evry"
Knakiballz (Talk | contribs) (Changed title and abstract to something more relevant.) |
Knakiballz (Talk | contribs) (Removed the immunity balance) |
||
| Line 22: | Line 22: | ||
a too important immune response can lead to food allergies or Inflammatory Bowel Disease. | a too important immune response can lead to food allergies or Inflammatory Bowel Disease. | ||
Absence of an immune response, in the other hand, plays a role in the spread of cancer cells.</p--> | Absence of an immune response, in the other hand, plays a role in the spread of cancer cells.</p--> | ||
| − | <div id="img-div"><img src="https://static.igem.org/mediawiki/2015/8/8a/Shcema_immune_syst.jpg" class="img-rounded img-responsive"></img></div> | + | <!--div id="img-div"><img src="https://static.igem.org/mediawiki/2015/8/8a/Shcema_immune_syst.jpg" class="img-rounded img-responsive"></img></div--> |
<!--p class="lead">Dendritic cells can orchestrate the immune response. By acting on them using engineered micro-organisms, | <!--p class="lead">Dendritic cells can orchestrate the immune response. By acting on them using engineered micro-organisms, | ||
we want to <a href="https://2015.igem.org/Team:Evry/Project/Induction">induce</a> or <a href="https://2015.igem.org/Team:Evry/Project/Repression">repress</a> the immune response when the immune system fails.</p--> | we want to <a href="https://2015.igem.org/Team:Evry/Project/Induction">induce</a> or <a href="https://2015.igem.org/Team:Evry/Project/Repression">repress</a> the immune response when the immune system fails.</p--> | ||
Revision as of 17:09, 12 August 2015
Welcome!
Abstract
Reshaping immunotherapy landscape.
Cancer thrives by preventing the immune system from targeting tumor cells. While current immunotherapies use dendritic cells to activate T-cells towards specific tumor antigens, they remain expensive and of variable efficiency against tumor immunosuppressive environment. To address these issues, our team mainly focused on engineering a S. cerevisiae yeast immunotherapy that was ultimately tested in vivo on mice presenting melanoma.
Three complementary strategies were combined: First, in order to modulate the tumor environment, yeast secreting immune modulators, GM-CSF and IFNgamma, were encapsulated into alginate beads and injected in tumors. Secondly, to break the immune tolerance against cancer cells, T4 and T8 lymphocytes were elicited by a yeast antigen display system. Last, to deliver cytotoxic compounds solely in the tumor environment, a yeast hypoxia bio-sensor was designed. A side project consisted in engineering E. coli to drive MAIT lymphocytes against cancer cells instead of their original targets, parasitized cells.
To top